Enzalutamide + Trastuzumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Amplified
Conditions
HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Timeline
Sep 5, 2014 → Jan 30, 2024
NCT ID
NCT02091960About Enzalutamide + Trastuzumab
Enzalutamide + Trastuzumab is a phase 2 stage product being developed by Astellas Pharma for HER2 Amplified. The current trial status is completed. This product is registered under clinical trial identifier NCT02091960. Target conditions include HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02091960 | Phase 2 | Completed |
Competing Products
20 competing products in HER2 Amplified